Kazia Therapeutics Limited

Compare

311 Followers

KZIA Stock Chart & Stats

$7.69

-$0.01(-0.57%)

At close: Jan 08 4:00 PM EST

$7.69

-$0.01(-0.57%)

Day’s Range― - ―

52-Week Range$2.86 - $39.05

Previous CloseN/A

Volume31.49K

Average Volume (3M)209.48K

Market Cap

$12.85M

Enterprise ValueN/A

Total Cash (Recent Filing)$3.06M

Total Debt (Recent Filing)$140.74K

Price to Earnings (P/E)―

Beta1.17

Next Earnings

Aug 28, 2025

EPS Estimate

>-0.01

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding1,670,578

10 Day Avg. Volume60,839

30 Day Avg. Volume209,481

Financial Highlights & Ratios

PEG Ratio0.00

Price to Book (P/B)-0.78

Price to Sales (P/S)3.38

P/FCF Ratio-0.82

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$16.50

Price Target Upside114.56% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Innovative PartnershipsKazia announced a new agreement with QIMR Berghofer to license a novel PD-L1 degrader program for development and commercialization, potentially making it a first mover in this new space.

Positive Clinical DataPaxalisib has shown an overall survival benefit in unmethylated GBM patients of approximately 15 months compared to 12 months with standard-of-care.

Regulatory SupportThe FDA appears supportive of developing therapies targeting high unmet needs with small patient populations, which may be a tailwind for paxalisib.

Bears Say

Clinical Trial ChallengesPaxalisib did not meet the primary endpoint in its Phase 2 studies, which may be a point of contention with the FDA.

Regulatory UncertaintyThere remains uncertainty on whether the FDA will request a pre-approval pivotal study prior to NDA submission, as the primary endpoint for all patients was not met in the study.

Kazia Therapeutics News

Kazia Therapeutics to request FDA Type C meeting

Kazia Therapeutics (KZIA) announced its intention to request and hold a follow-up Type C meeting with the U.S....

4d ago

KZIA

Kazia Therapeutics signs collaboration and in-licensing agreement for PD-L1

Kazia Therapeutics (KZIA) announced an exclusive collaboration and in-licensing agreement with QIMR Berghofer for a first-in-class PD-L1 degrader...

24d ago

KZIA

Kazia Therapeutics price target raised to $20 from $15 at Maxim

Maxim raised the firm’s price target on Kazia Therapeutics (KZIA) to $20 from $15 and keeps a Buy...

29d ago

KZIA

Kazia Therapeutics’ paxalisib combination shows tumor reduction

Kazia Therapeutics (KZIA) reported a substantial reduction in tumor burden from a single-patient expanded access case in triple-negative...

29d ago

KZIA

Buy Rating for Kazia Therapeutics Driven by Promising Paxalisib Developments and Regulatory Catalysts

Maxim Group analyst Naz Rahman reiterated a Buy rating on Kazia Therapeutics yesterday and set a price target...

2d ago

KZIA

Buy Rating for Kazia Therapeutics Driven by Strategic Drug Approval and Licensing Initiatives

Kazia Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Sean Lee CFA...

3d ago

KZIA

Strategic Advancements and Potential in Oncology: Kazia Therapeutics’ Buy Rating Driven by Novel PD-L1 Degrader and AI-Driven Paxalisib Development

Kazia Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Naz Rahman from...

20d ago

KZIA

Kazia Therapeutics Partners with QIMR Berghofer for Innovative PD-L1 Degrader Program

Kazia Therapeutics ( ($KZIA) ) has shared an update. On October 7, 2025, Kazia Therapeutics announced an exclusive...

23d ago

KZIA

Kazia Therapeutics Reports Significant Tumor Reduction in TNBC Patient with Paxalisib

Kazia Therapeutics ( ($KZIA) ) just unveiled an update. On October 2, 2025, Kazia Therapeutics announced an 86%...

29d ago

KZIA

Kazia Therapeutics files to sell 232,956 American Depositary Shares for holders

08:04 EDT Kazia Therapeutics (KZIA) files to sell 232,956 American Depositary Shares for holders Published first on TheFly...

1M ago

KZIA

Two new option listings and nine option delistings on September 22nd

New option listings for September 22nd include Netskope Inc (NTSK) and Sol Strategies Inc. (STKE). Option delistings effective...

1M ago

CMCT

FEAM

Buy Rating for Kazia Therapeutics Driven by Promising Paxalisib Developments in Cancer Treatment

Maxim Group analyst Naz Rahman reiterated a Buy rating on Kazia Therapeutics yesterday and set a price target...

2M ago

KZIA

Kazia Therapeutics Achieves Breakthrough in Breast Cancer Treatment with Paxalisib

Kazia Therapeutics ( ($KZIA) ) just unveiled an announcement. On September 11, 2025, Kazia Therapeutics announced significant findings...

2M ago

KZIA

Kazia Therapeutics’ paxalisib monotherapy shows tumor cell cluster disruption

Kazia Therapeutics (KZIA) announced new findings from a collaborative research program led by Professor Sudha Rao at QIMR...

2M ago

KZIA

KZIA FAQ

What was Kazia Therapeutics Limited’s price range in the past 12 months?

Kazia Therapeutics Limited lowest stock price was $2.86 and its highest was $39.05 in the past 12 months.

What is Kazia Therapeutics Limited’s market cap?

Kazia Therapeutics Limited’s market cap is $12.85M.

When is Kazia Therapeutics Limited’s upcoming earnings report date?

Kazia Therapeutics Limited’s upcoming earnings report date is Aug 28, 2025 which is 64 days ago.

How were Kazia Therapeutics Limited’s earnings last quarter?

Currently, no data Available

Is Kazia Therapeutics Limited overvalued?

According to Wall Street analysts Kazia Therapeutics Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Kazia Therapeutics Limited pay dividends?

Kazia Therapeutics Limited does not currently pay dividends.

What is Kazia Therapeutics Limited’s EPS estimate?

Kazia Therapeutics Limited’s EPS estimate is >-0.01.

How many shares outstanding does Kazia Therapeutics Limited have?

Kazia Therapeutics Limited has 1,670,578 shares outstanding.

What happened to Kazia Therapeutics Limited’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Kazia Therapeutics Limited?

Currently, no hedge funds are holding shares in KZIA

Company Description

Kazia Therapeutics Limited

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Kazia Therapeutics (KZIA) Earnings & Revenues

Historic Earnings Reports

KZIA Stock 12 Month Forecast

Average Price Target

$16.50

▲(114.56% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","337":"$337","85.75":"$85.8","169.5":"$169.5","253.25":"$253.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$16.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$13.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,85.75,169.5,253.25,337],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2023","6":"Feb<br/>2025","9":"Jun<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.85,7.861538461538461,8.873076923076923,9.884615384615383,10.896153846153846,11.907692307692308,12.919230769230769,13.93076923076923,14.942307692307692,15.953846153846152,16.965384615384615,17.97692307692308,18.988461538461536,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.85,7.592307692307692,8.334615384615384,9.076923076923077,9.819230769230769,10.561538461538461,11.303846153846154,12.046153846153846,12.788461538461538,13.53076923076923,14.273076923076923,15.015384615384615,15.757692307692308,{"y":16.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.85,7.323076923076923,7.796153846153846,8.269230769230768,8.742307692307692,9.215384615384615,9.688461538461539,10.161538461538461,10.634615384615385,11.107692307692307,11.580769230769231,12.053846153846154,12.526923076923076,{"y":13,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":336.5,"date":1646092800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":288,"date":1654041600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":96,"date":1659312000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.5,"date":1680307200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.84,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.85,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":7.9,"date":1738368000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":3.98,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":3.93,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.78,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.63,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.79,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.85,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >